Review



shp 2  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress shp 2
    Shp 2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/shp 2/product/MedChemExpress
    Average 94 stars, based on 12 article reviews
    shp 2 - by Bioz Stars, 2026-02
    94/100 stars

    Images



    Similar Products

    shp 2  (MedChemExpress)
    94
    MedChemExpress shp 2
    Shp 2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/shp 2/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    shp 2 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    shp2  (MedChemExpress)
    94
    MedChemExpress shp2
    ANOVA, analysis of variance; EC, endometrial cancer; EEC, endometrial epithelial cell; NC, negative control; OD, optical density; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; SD, standard deviation; <t>SHP2,</t> src homology phosphotyrosin phosphatase 2. * p<0.05.
    Shp2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/shp2/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    shp2 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    sh2  (MedChemExpress)
    94
    MedChemExpress sh2
    ANOVA, analysis of variance; EC, endometrial cancer; EEC, endometrial epithelial cell; NC, negative control; OD, optical density; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; SD, standard deviation; <t>SHP2,</t> src homology phosphotyrosin phosphatase 2. * p<0.05.
    Sh2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sh2/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    sh2 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    ANOVA, analysis of variance; EC, endometrial cancer; EEC, endometrial epithelial cell; NC, negative control; OD, optical density; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; SD, standard deviation; SHP2, src homology phosphotyrosin phosphatase 2. * p<0.05.

    Journal: Journal of Gynecologic Oncology

    Article Title: TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway

    doi: 10.3802/jgo.2024.35.e64

    Figure Lengend Snippet: ANOVA, analysis of variance; EC, endometrial cancer; EEC, endometrial epithelial cell; NC, negative control; OD, optical density; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; SD, standard deviation; SHP2, src homology phosphotyrosin phosphatase 2. * p<0.05.

    Article Snippet: EC cell lines in which SHP2 was stably knocked down were treated with the EGFR signaling pathway activator 10 μM Isoprocurcumenol (HY-113599, MedChemExpress, Monmouth Junction, NJ, USA) or DMSO (named Activator-NC thereafter) for 48 hours for subsequent experiments.

    Techniques: Negative Control, Quantitative RT-PCR, Reverse Transcription, Real-time Polymerase Chain Reaction, Standard Deviation

    EC, endometrial cancer; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; IC50, median inhibition concentration; MPA, medroxyprogesterone acetate; NC, negative control; SD, standard deviation; SHP2, src homology phosphotyrosin phosphatase 2. *,† p<0.05.

    Journal: Journal of Gynecologic Oncology

    Article Title: TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway

    doi: 10.3802/jgo.2024.35.e64

    Figure Lengend Snippet: EC, endometrial cancer; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; IC50, median inhibition concentration; MPA, medroxyprogesterone acetate; NC, negative control; SD, standard deviation; SHP2, src homology phosphotyrosin phosphatase 2. *,† p<0.05.

    Article Snippet: EC cell lines in which SHP2 was stably knocked down were treated with the EGFR signaling pathway activator 10 μM Isoprocurcumenol (HY-113599, MedChemExpress, Monmouth Junction, NJ, USA) or DMSO (named Activator-NC thereafter) for 48 hours for subsequent experiments.

    Techniques: Inhibition, Concentration Assay, Negative Control, Standard Deviation

    EC, endometrial cancer; 5hmC, 5-hydroxymethylcytosine; IgG, immunoglobulin G; NC, negative control; NCBI, National Center for Biotechnology Information; qPCR, quantitative polymerase chain reaction; SD, standard deviation; SHP2, src homology phosphotyrosin phosphatase 2; TET, ten-eleven translocation. * p<0.05.

    Journal: Journal of Gynecologic Oncology

    Article Title: TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway

    doi: 10.3802/jgo.2024.35.e64

    Figure Lengend Snippet: EC, endometrial cancer; 5hmC, 5-hydroxymethylcytosine; IgG, immunoglobulin G; NC, negative control; NCBI, National Center for Biotechnology Information; qPCR, quantitative polymerase chain reaction; SD, standard deviation; SHP2, src homology phosphotyrosin phosphatase 2; TET, ten-eleven translocation. * p<0.05.

    Article Snippet: EC cell lines in which SHP2 was stably knocked down were treated with the EGFR signaling pathway activator 10 μM Isoprocurcumenol (HY-113599, MedChemExpress, Monmouth Junction, NJ, USA) or DMSO (named Activator-NC thereafter) for 48 hours for subsequent experiments.

    Techniques: Negative Control, Real-time Polymerase Chain Reaction, Standard Deviation, Translocation Assay

    EC, endometrial cancer; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; IC50, median inhibition concentration; MPA, medroxyprogesterone acetate; NC, negative control; SD, standard deviation; SHP2, src homology phosphotyrosin phosphatase 2; TET3, ten-eleven translocation 3. *,† p<0.05.

    Journal: Journal of Gynecologic Oncology

    Article Title: TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway

    doi: 10.3802/jgo.2024.35.e64

    Figure Lengend Snippet: EC, endometrial cancer; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; IC50, median inhibition concentration; MPA, medroxyprogesterone acetate; NC, negative control; SD, standard deviation; SHP2, src homology phosphotyrosin phosphatase 2; TET3, ten-eleven translocation 3. *,† p<0.05.

    Article Snippet: EC cell lines in which SHP2 was stably knocked down were treated with the EGFR signaling pathway activator 10 μM Isoprocurcumenol (HY-113599, MedChemExpress, Monmouth Junction, NJ, USA) or DMSO (named Activator-NC thereafter) for 48 hours for subsequent experiments.

    Techniques: Inhibition, Concentration Assay, Negative Control, Standard Deviation, Translocation Assay

    EC, endometrial cancer; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; MPA, medroxyprogesterone acetate; NC, negative control; SHP2, src homology phosphotyrosin phosphatase 2; TET3, ten-eleven translocation 3. *,† p<0.05.

    Journal: Journal of Gynecologic Oncology

    Article Title: TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway

    doi: 10.3802/jgo.2024.35.e64

    Figure Lengend Snippet: EC, endometrial cancer; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; MPA, medroxyprogesterone acetate; NC, negative control; SHP2, src homology phosphotyrosin phosphatase 2; TET3, ten-eleven translocation 3. *,† p<0.05.

    Article Snippet: EC cell lines in which SHP2 was stably knocked down were treated with the EGFR signaling pathway activator 10 μM Isoprocurcumenol (HY-113599, MedChemExpress, Monmouth Junction, NJ, USA) or DMSO (named Activator-NC thereafter) for 48 hours for subsequent experiments.

    Techniques: Negative Control, Translocation Assay